161 related articles for article (PubMed ID: 31843580)
1. Introducing a panel for early detection of lung adenocarcinoma by using data integration of genomics, epigenomics, transcriptomics and proteomics.
Haghjoo N; Moeini A; Masoudi-Nejad A
Exp Mol Pathol; 2020 Feb; 112():104360. PubMed ID: 31843580
[TBL] [Abstract][Full Text] [Related]
2. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
3. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of microRNAs derived from exosomes in bronchoalveolar lavage fluid of early-stage lung adenocarcinoma: A pilot study.
Kim JE; Eom JS; Kim WY; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Kim MH
Thorac Cancer; 2018 Aug; 9(8):911-915. PubMed ID: 29806739
[TBL] [Abstract][Full Text] [Related]
5. EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.
Shao B; Bjaanæs MM; Helland Å; Schütte C; Conrad T
PLoS One; 2019; 14(1):e0204186. PubMed ID: 30703089
[TBL] [Abstract][Full Text] [Related]
6. A panel of miRNAs derived from plasma extracellular vesicles as novel diagnostic biomarkers of lung adenocarcinoma.
Yao B; Qu S; Hu R; Gao W; Jin S; Liu M; Zhao Q
FEBS Open Bio; 2019 Dec; 9(12):2149-2158. PubMed ID: 31677346
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis of inborn errors of metabolism by an integrative "multi-omics" approach: A perspective encompassing genomics, transcriptomics, and proteomics.
Stenton SL; Kremer LS; Kopajtich R; Ludwig C; Prokisch H
J Inherit Metab Dis; 2020 Jan; 43(1):25-35. PubMed ID: 31119744
[TBL] [Abstract][Full Text] [Related]
8. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
9. Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer.
Asada K; Kobayashi K; Joutard S; Tubaki M; Takahashi S; Takasawa K; Komatsu M; Kaneko S; Sese J; Hamamoto R
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32235589
[TBL] [Abstract][Full Text] [Related]
10. Network-Based Integrative Analysis of Genomics, Epigenomics and Transcriptomics in Autism Spectrum Disorders.
Di Nanni N; Bersanelli M; Cupaioli FA; Milanesi L; Mezzelani A; Mosca E
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31323926
[TBL] [Abstract][Full Text] [Related]
11. Integrated quantitative proteomic and transcriptomic analysis of lung tumor and control tissue: a lung cancer showcase.
Tenzer S; Leidinger P; Backes C; Huwer H; Hildebrandt A; Lenhof HP; Wesse T; Franke A; Meese E; Keller A
Oncotarget; 2016 Mar; 7(12):14857-70. PubMed ID: 26930711
[TBL] [Abstract][Full Text] [Related]
12. [Identification of disease targets for precision medicine by integrative analysis of multi-omics data].
Xie BB; Yang YD; Ding N; Fang XD
Yi Chuan; 2015 Jul; 37(7):655-63. PubMed ID: 26351165
[TBL] [Abstract][Full Text] [Related]
13. Identification of an early diagnostic biomarker of lung adenocarcinoma based on co-expression similarity and construction of a diagnostic model.
Fan Z; Xue W; Li L; Zhang C; Lu J; Zhai Y; Suo Z; Zhao J
J Transl Med; 2018 Jul; 16(1):205. PubMed ID: 30029648
[TBL] [Abstract][Full Text] [Related]
14. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumor suppressor miRNAs by integrative miRNA and mRNA sequencing of matched tumor-normal samples in lung adenocarcinoma.
Yu N; Yong S; Kim HK; Choi YL; Jung Y; Kim D; Seo J; Lee YE; Baek D; Lee J; Lee S; Lee JE; Kim J; Kim J; Lee S
Mol Oncol; 2019 Jun; 13(6):1356-1368. PubMed ID: 30913346
[TBL] [Abstract][Full Text] [Related]
16. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
Kim D; Li R; Dudek SM; Ritchie MD
J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.
Liu WT; Wang Y; Zhang J; Ye F; Huang XH; Li B; He QY
Cancer Lett; 2018 Jul; 425():43-53. PubMed ID: 29608985
[TBL] [Abstract][Full Text] [Related]
18. Development of a miRNA-seq based prognostic signature in lung adenocarcinoma.
Siriwardhana C; Khadka VS; Chen JJ; Deng Y
BMC Cancer; 2019 Jan; 19(1):34. PubMed ID: 30621620
[TBL] [Abstract][Full Text] [Related]
19. [Omics technologies in diagnostics of lung adenocarcinoma].
Novikova SE; Kurbatov LK; Zavialova MG; Zgoda VG; Archakov AI
Biomed Khim; 2017 May; 63(3):181-210. PubMed ID: 28781253
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of multi-omics integration tools for cancer driver gene identification and tumour subtyping.
Sathyanarayanan A; Gupta R; Thompson EW; Nyholt DR; Bauer DC; Nagaraj SH
Brief Bioinform; 2020 Dec; 21(6):1920-1936. PubMed ID: 31774481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
